BR0011714A - Medicamento oftalmológico neuro-protetor e retino-protetor e utilização de um princìpio ativo de medicamento - Google Patents

Medicamento oftalmológico neuro-protetor e retino-protetor e utilização de um princìpio ativo de medicamento

Info

Publication number
BR0011714A
BR0011714A BR0011714-5A BR0011714A BR0011714A BR 0011714 A BR0011714 A BR 0011714A BR 0011714 A BR0011714 A BR 0011714A BR 0011714 A BR0011714 A BR 0011714A
Authority
BR
Brazil
Prior art keywords
protective
medicine
retinal
ramiprilat
neuro
Prior art date
Application number
BR0011714-5A
Other languages
English (en)
Inventor
Raouf Rekik
Original Assignee
Elyes Ben Mohamed Raouf Rekik
Raouf Rekik
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR9915359A external-priority patent/FR2794975A1/fr
Application filed by Elyes Ben Mohamed Raouf Rekik, Raouf Rekik filed Critical Elyes Ben Mohamed Raouf Rekik
Publication of BR0011714A publication Critical patent/BR0011714A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Saccharide Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)

Abstract

"MEDICAMENTO OFTALMOLóGICO NEURO-PROTETOR E RETINO-PROTETOR E UTILIZAçãO DE UM PRINCìPIO ATIVO DE MEDICAMENTO". A invenção refere-se a um medicamento neuro-protetor e retino-protetor, cujo principio ativo é escolhido dentre um grupo de compostos consistindo de ramipril, o ramiprilato ou qualquer outro derivado de ramiprilato susceptível de liberar o mesmo no organismo, em que ele será administrado. Ela é aplicada à prevenção, ou mesmo melhora da acuidade visual e do campo visual junto aos indivíduos normais, assim como ao tratamento de patologias oftálmicas empregando um fator vascular, notadamente de neuropatias glaucomatosas, corio-retinopatias degenerativas do forte míope, das degenerescências maculares ligadas à idade, de corioretinopatias serosas centrais, distrofias hereditárias da retina e oclusões venosas retinianas. Ela acarreta praticamente sempre uma melhora da função visual (acuidade e campo visual).
BR0011714-5A 1999-06-16 2000-06-16 Medicamento oftalmológico neuro-protetor e retino-protetor e utilização de um princìpio ativo de medicamento BR0011714A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
TN99122 1999-06-16
FR9915359A FR2794975A1 (fr) 1999-06-16 1999-12-06 Medicaments opthalmologiques neuro et retino-protecteurs
PCT/FR2000/001679 WO2000076499A2 (fr) 1999-06-16 2000-06-16 Medicaments ophtalmologiques neuro-et retino-protecteurs

Publications (1)

Publication Number Publication Date
BR0011714A true BR0011714A (pt) 2002-03-05

Family

ID=26235177

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0011714-5A BR0011714A (pt) 1999-06-16 2000-06-16 Medicamento oftalmológico neuro-protetor e retino-protetor e utilização de um princìpio ativo de medicamento

Country Status (20)

Country Link
US (1) US7049340B1 (pt)
EP (1) EP1185255B1 (pt)
JP (1) JP2003501461A (pt)
AT (1) ATE424819T1 (pt)
AU (1) AU6449000A (pt)
BR (1) BR0011714A (pt)
CA (1) CA2376909A1 (pt)
CZ (1) CZ20014516A3 (pt)
DE (1) DE60041765D1 (pt)
DK (1) DK1185255T3 (pt)
ES (1) ES2324200T3 (pt)
HU (1) HUP0201478A3 (pt)
MA (1) MA26798A1 (pt)
MX (1) MXPA01012907A (pt)
NO (1) NO20016088L (pt)
PL (1) PL352365A1 (pt)
SI (1) SI1185255T1 (pt)
SK (1) SK18772001A3 (pt)
TR (1) TR200103665T2 (pt)
WO (1) WO2000076499A2 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2826276A1 (fr) * 2001-06-20 2002-12-27 Raouf Rekik Administration des inhibiteurs de l'enzyme de conversion de l'angiotensine dans les degradations visuelles des sujets ages dues a la presbytie
EP2021000A2 (en) * 2006-05-09 2009-02-11 Braincells, Inc. Neurogenesis by modulating angiotensin
US7858611B2 (en) 2006-05-09 2010-12-28 Braincells Inc. Neurogenesis by modulating angiotensin
TNSN08110A1 (en) * 2008-03-11 2009-07-14 Rekik Raouf Dr Drug delivery to the anterior and posterior segment of the eye from drops
TN2010000566A1 (en) * 2010-12-03 2012-05-24 Rekik Raouf Folic acid - ramipril combination : cell protective neuroprotective and retinoprotective ophtalmologic drugs
RU2471454C2 (ru) * 2010-12-14 2013-01-10 Валерий Викторович Педдер Способ лечения дистрофических заболеваний сетчатки глаза
CA2877590A1 (en) * 2012-06-29 2014-01-03 Raouf Rekik Angiotensin converting enzyme inhibitors for treating optic neuropathy or congenital optic atrophy

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3381850D1 (de) * 1982-12-27 1990-10-04 Schering Corp Pharmazeutische zusammensetzung.
DE3410732A1 (de) * 1984-03-23 1985-09-26 Hoechst Ag, 6230 Frankfurt Methode zur behandlung des glaukoms
US4656188A (en) * 1985-10-09 1987-04-07 Merck & Co., Inc. Ace inhibitors in macular degeneration
JPH05306296A (ja) * 1992-04-24 1993-11-19 Marino Forum 21 魚類由来ペプチドとその製法
WO1999036062A1 (en) * 1998-01-16 1999-07-22 Alcon Laboratories, Inc. Topical administration of angiotensin-converting enzyme inhibitors

Also Published As

Publication number Publication date
PL352365A1 (en) 2003-08-25
CA2376909A1 (fr) 2000-12-21
US7049340B1 (en) 2006-05-23
SI1185255T1 (sl) 2009-08-31
AU6449000A (en) 2001-01-02
HUP0201478A2 (hu) 2002-11-28
ATE424819T1 (de) 2009-03-15
SK18772001A3 (sk) 2002-04-04
MA26798A1 (fr) 2004-12-20
DK1185255T3 (da) 2009-07-06
DE60041765D1 (de) 2009-04-23
ES2324200T3 (es) 2009-08-03
EP1185255A2 (fr) 2002-03-13
MXPA01012907A (es) 2003-06-24
TR200103665T2 (tr) 2002-10-21
CZ20014516A3 (cs) 2002-05-15
EP1185255B1 (fr) 2009-03-11
NO20016088D0 (no) 2001-12-13
HUP0201478A3 (en) 2004-05-28
WO2000076499A2 (fr) 2000-12-21
JP2003501461A (ja) 2003-01-14
NO20016088L (no) 2002-02-12
WO2000076499A3 (fr) 2001-05-17

Similar Documents

Publication Publication Date Title
Messerli et al. Renal denervation for resistant hypertension
Kumar et al. A review of sub-Tenon's block: current practice and recent development
WO2003089033A8 (en) Implantable drug delivery system responsive to intra-cardiac pressure
DK1576970T3 (da) Intraluminal indretning med en coating, der indeholder et terapeutisk middel
BR0109336A (pt) Medicamento para a prevenção, melhora e/ou tratamento de uma complicação diabética, droga medicinal adequada ou utilizável como o mesmo, método para prevenir, melhorar e/ou tratar a complicação diabética, e a neuropatia, e, usos de um agente redutor do açúcar no sangue pós-prandial e pelo menos um agente selecionado de um agente anti-hipertensivo, um agente vasodilatador e um agente anti-hiperlipidêmico
Hosseini et al. Comparison between topical and oral tranexamic acid in management of traumatic hyphema
WO2001089537A3 (en) Apoptotic entities for use in treatment of neurodegenerative and other neurological disorders
MA26798A1 (fr) Medicaments ophtalmologiques neuro-et retino-protecteurs
Coffey et al. Ascorbic acid deficiency and aspirin-induced haematemesis
DK30092D0 (da) Fremgangsmaade og midler til ikke-invasiv aedosis-til-virkningae administration af lipofile laegemidler
Avetisov et al. Effect of vasoactive agents on visual functions and ocular blood flow in patients with early manifestations of age-related macular degeneration
Jones et al. Does EMLA reduce the discomfort associated with local‐anaesthetic infiltration?
ES2182840T3 (es) Factor xiii para el tratamiento de heridas de la piel.
Ravani et al. “Dye front reciprocation” in combined central retinal vein occlusion with cilioretinal artery infarction
Schiemann et al. Coincidence of cytomegalovirus retinitis and central retinal vein occlusion in a patient with hemophilia B and AIDS
RU2290191C2 (ru) Способ лечения туберкулезных увеитов
Goldberg Comparison of tropical travoprost eye drops given once daily and timolol 0.5% given twice daily in patients with open-angle glaucoma or ocular hypertension. J. Glaucoma 2001; 10: 414-22
Shariq et al. Managing cysticercosis in anterior chamber of eye: a case report
CY1110476T1 (el) Οφθαλμολογικα φαρμακα προστατευτικα του αμφιβληστροειδους τα οποια περιεχουν ραμιπριλη ή ραμιπριλατη
Walters Paediatric treatment issues
Kachwalla et al. Spontaneous coronary dissection following exertion: support for a hypothesis
Biller latrogenic neurology
Medvei Lightning
OHGI et al. CATHETER-RELATED DEEP VEIN THROMBOSIS
Mitchell et al. Care of the elderly patient receiving continuous 5-Fluorouracil at home

Legal Events

Date Code Title Description
FA10 Dismissal: dismissal - article 33 of industrial property law
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]